Abrocitinib Manufacturing Process Patent in 2024
The patent landscape for abrocitinib, a drug used to treat atopic dermatitis, includes filings related to its manufacturing process. These patents are crucial for protecting the methods by which the drug is produced.
What is the Status of Abrocitinib Manufacturing Patents?
As of 2024, patents specifically covering improved manufacturing processes for abrocitinib are part of the broader intellectual property surrounding the drug. Companies often seek patents for novel or more efficient ways to synthesize active pharmaceutical ingredients like abrocitinib to maintain market exclusivity. Detailed information on specific patent filings and their current status can be found through patent databases and specialized resources like DrugPatentWatch.com [1].
How are Drug Manufacturing Patents Different from Drug Composition Patents?
Drug patents generally fall into several categories, including those for the active pharmaceutical ingredient itself (composition of matter), methods of use for treating specific conditions, and manufacturing processes. A patent on a manufacturing process protects the specific steps, reagents, or conditions used to create the drug. This differs from a composition of matter patent, which protects the drug molecule itself, or a method of use patent, which protects the application of the drug for a particular medical purpose. Protecting manufacturing processes can extend a drug's market exclusivity even after primary composition patents expire, particularly if the patented process offers significant advantages in cost, purity, or efficiency.
When Does Abrocitinib's Intellectual Property Protection Expire?
The expiration dates for abrocitinib's patents, including those related to its manufacturing, are critical for determining when generic or biosimilar competition may enter the market. Patents have a limited term, typically 20 years from the filing date. However, various factors can affect the effective market exclusivity period, such as patent term extensions due to regulatory delays and the filing of additional patents for new indications or improved formulations and manufacturing methods. For precise details on abrocitinib's patent expiration, resources like DrugPatentWatch.com offer comprehensive and up-to-date information [1].
Who Holds Patents for Abrocitinib Manufacturing?
Pfizer Inc. is the developer of abrocitinib (marketed as Cibinqo). As the innovator company, Pfizer is the primary holder of patents related to abrocitinib, including those covering its composition, methods of use, and manufacturing processes [1].
What are the Implications of Manufacturing Patents for Drug Pricing and Availability?
Patents on manufacturing processes can influence drug pricing and availability by extending market exclusivity for the innovator company. If a patented manufacturing process is significantly more efficient or results in a purer product, it can create a barrier to entry for potential competitors. Generic manufacturers must find ways to produce the drug without infringing on existing patents, which can involve developing alternative synthesis routes. This process can delay the availability of lower-cost generic alternatives, potentially keeping prices higher for a longer period.
Can Generic Versions of Abrocitinib Be Developed if Manufacturing Patents are Still Active?
The development of generic versions of abrocitinib is contingent upon the expiration of relevant patents, including those covering the drug's composition and potentially its manufacturing processes. Generic drug manufacturers must demonstrate that their product is bioequivalent to the brand-name drug and that their manufacturing process does not infringe on any valid and unexpired patents. If a key manufacturing process patent remains in effect, generic companies may need to develop entirely different synthesis methods to bring their products to market.
What are the Potential Risks or Challenges Related to Abrocitinib Patents?
The primary risk associated with patents for pharmaceutical products like abrocitinib is patent litigation. Competitors may challenge the validity of existing patents, leading to legal battles that can impact market exclusivity. Additionally, the complexity of pharmaceutical patents means that unintended overlaps or ambiguities can arise, creating uncertainty for both innovators and generic manufacturers. The pursuit of process patents can also be a strategy to extend market exclusivity beyond the term of the original composition of matter patent, a practice that sometimes draws scrutiny from regulatory bodies and the public.
Sources:
[1] DrugPatentWatch.com